Alpha 2.0
Login Register
» Authors » Joby Mathew

Joby Mathew

Explore the profile of Joby Mathew including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 12
Citations 60
Followers 0
Related Specialties
General Surgery
Pulmonary Medicine
Cardiology & Vascular Diseases
Top 10 Co-Authors
Sean Agbor-Enoh
Pali Shah
Steven D Nathan
Shambhu Aryal
Hyesik Kong
Helen Luikart
Pali D Shah
Nitipong Permpalung
Kiran K Khush
Katrina Bazemore
Published In
J Heart Lung Transplant
Transplantation
Am J Transplant
Conn Med
J Appl Lab Med
Affiliations
Soon will be listed here.
Recent Articles
1.
Baseline Lung Allograft Dysfunction After Bilateral Lung Transplantation Is Associated With an Increased Risk of Death: Results From a Multicenter Cohort Study
Keller M, Sun J, Alnababteh M, Ponor L, Shah P, Mathew J, et al.
Transplant Direct . 2024 Jul; 10(7):e1669. PMID: 38953039
Background: A prior single-center, retrospective cohort study identified baseline lung allograft dysfunction (BLAD) as a risk factor for death in bilateral lung transplant recipients. In this multicenter prospective cohort study,...
2.
Extreme elevations of donor-derived cell-free DNA increases the risk of chronic lung allograft dysfunction and death, even without clinical manifestations of disease
Keller M, Newman D, Alnababteh M, Ponor L, Shah P, Mathew J, et al.
J Heart Lung Transplant . 2024 May; 43(9):1374-1382. PMID: 38705500
Background: Lung transplant recipients are traditionally monitored with pulmonary function testing (PFT) and lung biopsy to detect post-transplant complications and guide treatment. Plasma donor-derived cell free DNA (dd-cfDNA) is a...
3.
Pseudomonas-dominant microbiome elicits sustained IL-1β upregulation in alveolar macrophages from lung transplant recipients
Britton N, Villabona-Rueda A, Whiteside S, Mathew J, Kelley M, Agbor-Enoh S, et al.
J Heart Lung Transplant . 2023 Apr; 42(9):1166-1174. PMID: 37088343
Background: Isolation of Pseudomonas aeruginosa (PsA) is associated with increased BAL (bronchoalveolar lavage) inflammation and lung allograft injury in lung transplant recipients (LTR). However, the effect of PsA on macrophage...
4.
Invasive fungal infections after respiratory viral infections in lung transplant recipients are associated with lung allograft failure and chronic lung allograft dysfunction within 1 year
Permpalung N, Liang T, Gopinath S, Bazemore K, Mathew J, Ostrander D, et al.
J Heart Lung Transplant . 2023 Mar; 42(7):953-963. PMID: 36925381
Background: Respiratory viral infections (RVI) are associated with chronic lung allograft dysfunction (CLAD) and mortality in lung transplant recipients (LTRs). However, the prevalence and impact of secondary invasive fungal infections...
5.
Preemptive treatment of de novo donor-specific antibodies in lung transplant patients reduces subsequent risk of chronic lung allograft dysfunction or death
Keller M, Yang S, Ponor L, Bon A, Cochrane A, Philogene M, et al.
Am J Transplant . 2023 Feb; 23(4):559-564. PMID: 36732088
The development of donor-specific antibodies after lung transplantation is associated with downstream acute cellular rejection, antibody-mediated rejection (AMR), chronic lung allograft dysfunction (CLAD), or death. It is unknown whether preemptive...
6.
Clinical features and allograft failure rates of pulmonary antibody-mediated rejection categories
Charya A, Ponor I, Cochrane A, Levine D, Philogene M, Fu Y, et al.
J Heart Lung Transplant . 2022 Nov; 42(2):226-235. PMID: 36319530
Background: Pulmonary antibody-mediated rejection (AMR) consensus criteria categorize AMR by diagnostic certainty. This study aims to define the clinical features and associated outcomes of these recently defined AMR categories. Methods:...
7.
Elevated cell-free DNA in respiratory viral infection and associated lung allograft dysfunction
Bazemore K, Permpalung N, Mathew J, Lemma M, Haile B, Avery R, et al.
Am J Transplant . 2022 Jun; 22(11):2560-2570. PMID: 35729715
Respiratory viral infection (RVI) in lung transplant recipients (LTRs) is a risk for chronic lung allograft dysfunction (CLAD). We hypothesize that donor-derived cell-free DNA (%ddcfDNA), at the time of RVI...
8.
Donor-derived cell-free DNA as a composite marker of acute lung allograft dysfunction in clinical care
Keller M, Sun J, Mutebi C, Shah P, Levine D, Aryal S, et al.
J Heart Lung Transplant . 2022 Jan; 41(4):458-466. PMID: 35063338
Background: As a marker of underlying lung allograft injury, donor-derived cell-free DNA (dd-cfDNA) may be used to identify episodes of acute allograft injury in lung transplant recipients. We investigated the...
9.
Biological Variation of Donor-Derived Cell-Free DNA in Stable Lung Transplant Recipients
Keller M, Mutebi C, Shah P, Levine D, Aryal S, Iacono A, et al.
J Appl Lab Med . 2022 Jan; 7(4):901-909. PMID: 35024828
Background: Prior studies demonstrate that donor-derived cell-free DNA (dd-cfDNA) in lung transplant recipients may serve as a marker of allograft injury for detecting allograft rejection and infection. Clinical interpretation of...
10.
Impact of COVID-19 on Lung Allograft and Clinical Outcomes in Lung Transplant Recipients: A Case-control Study
Permpalung N, Bazemore K, Chiang T, Mathew J, Barker L, Nematollahi S, et al.
Transplantation . 2021 Jun; 105(9):2072-2079. PMID: 34075005
Background: The impacts of COVID-19 on lung allograft function, rejection, secondary infection, and clinical outcomes in lung transplant recipients (LTRs) remain unknown. Methods: A 1:2 matched case-control study was performed...